{'fraction_non_alphanumeric': 0.03490990990990991, 'fraction_numerical': 0.0033783783783783786, 'mean_word_length': 5.442028985507246, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Renal denervation – not an easy road to treatment of arterial hypertension and concomitant diseases

Percutaneous renal denervation (RDN) has been introduced in clinical trials as the possible interventional method of treatment of resistant hypertension more than one decade ago. The results of trials: SYMPLICITY HTN-1 (single-arm), HTN-2 (randomized, single-blinded) and HTN-3 (with sham procedure) are summarized in this article. The author presents the results of second-generation trials with new technologies: Spyral catheter (radiofrequency RDN) and Paradise system (ultrasound RDN). The favorable results of these studies justify the revision of the current recommendations, limiting this method only to clinical trials. Also the studies on RDN applied in atrial fibrillation and obstructive sleep apnea – diseases related to sympathetic nervous system activity – are discussed.

